Crohn’s disease causes inflammation that spreads deeply into the layers of bowel tissue and can lead to life threatening complications. Crohn’s disease is a lifelong chronic condition that ...

Crohn’s disease is a chronic condition that can lead to other digestive problems, including gallbladder disease. Crohn’s disease is a condition in which recurrent inflammation affects your bowels.

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...

A research team led by Mount Sinai has uncovered mechanisms of abnormal immune cell function that may lead to Crohn's disease ...

Since Crohn's disease is clinically and histopathologically similar to tuberculosis, leprosy and paratuberculosis, it has been suggested that the disease is caused by a mycobacterial infection.

Crohn's disease and ulcerative colitis are idiopathic, chronic, relapsing, inflammatory conditions that are immunologically mediated. Although their exact etiologies remain uncertain, results from ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel ...

RedHill Biopharma (RDHL) announced plans to advance its groundbreaking late-stage program for Crohn’s disease, or CD, with initiation of an ...

“Before a trip, I worry that my Crohn’s disease might flare up, even if I’m currently in remission,” she says. “I get anxious about what restroom facilities I'll have near me, the ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

French biotech moves on with the late stage drug development, after publishing impressive clinical trial results of ABX464 for treatment of colitis and hinting its potential in Crohn’s disease.